May 3, 2022 | Deerfield, IL

The Board of Directors of Baxter International Inc. has declared a regular quarterly dividend of $0.29 per common share, an increase of approximately 3.5% over the previous quarterly dividend.

Year to date, this marks the fourteenth dividend announcement for the Washington Crossing Advisors Rising Dividend portfolio.

From the press release: “Baxter International Inc. (NYSE:BAX), a leading global medtech company, today announced an increase in the company’s quarterly cash dividend to a rate of $0.29 per share of common stock. This represents an approximately 3.5% increase over the previous quarterly dividend rate of $0.28 per share. Baxter’s Board of Directors declared the dividend payable on July 1, 2022, to stockholders of record as of June 3, 2022. The indicated annual dividend rate is now $1.16 per share of common stock.

“Baxter continues to advance its lifesaving Mission and deliver value for shareholders amid an unprecedented healthcare landscape,” said José (Joe) E. Almeida, chairman, president and chief executive officer. “With our dedicated employees, diverse portfolio and disciplined approach to capital allocation, we are pleased to increase our dividend for the seventh straight year. We will continue to focus on advancing innovation, accelerating growth and realizing the potential of our Hillrom acquisition to benefit patients, caregivers, investors and the many other stakeholder communities that depend on us.””1

About the company: “Every day, millions of patients, caregivers and healthcare providers rely on Baxter’s leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For 90 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook.”1


IMPORTANT DISCLOSURES: The securities discussed herein do not represent all of the securities held by the WCA Rising Dividend Portfolio as of the date presented and are subject to change at any time, without notice. A complete list of holdings as of the date noted above will be provided upon request. The above is presented to illustrate the application of the strategy only and not intended as personalized recommendations of any particular security. The securities identified and described above do not represent all of the securities purchased, sold, or recommended for client accounts. You should not assume that an investment in any of the securities identified was or will be profitable. Changes in market conditions or a company’s financial condition may impact the company’s ability to continue to pay dividends. Companies may also choose to discontinue dividend payments. All investments involve risk, including loss of principal, and there is no guarantee that investment objectives will be met. It is important to review your investment objectives, risk tolerance and liquidity needs before choosing an investment style or manager. Equity investments are subject generally to market, market sector, market liquidity, issuer, and investment style risks, among other factors to varying degrees. Fixed Income investments are subject to market, market liquidity, issuer, investment style, interest rate, credit quality, and call risks, among other factors to varying degrees.